P1017: HARBOR: A PHASE 2/3 STUDY OF BLU-263 IN PATIENTS WITH INDOLENT SYSTEMIC MASTOCYTOSIS AND MONOCLONAL MAST CELL ACTIVATION SYNDROME

• M. Castells,
• R. Scherber,
• V. Bhavsar,
• K. He,
• C. Akin

Affiliations

M. Castells

1 Mastocytosis Center, Brigham and Women’s Hospital and Harvard Medical School, Boston

R. Scherber

2 Blueprint Medicines Corporation, Cambridge

V. Bhavsar

2 Blueprint Medicines Corporation, Cambridge

K. He

2 Blueprint Medicines Corporation, Cambridge

C. Akin

4 University of Michigan, Ann Arbor, United States of America